Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression

Pharmacological Research

Volumn 61, Issue 1, 2010, Pages 34-39

  Matsui, Takanori ^a   Yamagishi, Sho ichi ^a   Takeuchi, Masayoshi ^b   Ueda, Seiji ^a   Fukami, Kei ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; Diabetic nephropathy; RAGE; RAS

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CASPASE 3; DNA FRAGMENT; IRBESARTAN; MESSENGER RNA; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; KIDNEY TUBULE DAMAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; APOPTOSIS; BIPHENYL COMPOUNDS; CASPASE 3; CELLS, CULTURED; DOWN-REGULATION; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY TUBULES, PROXIMAL; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; SERUM ALBUMIN, BOVINE; TETRAZOLES;

EID: 72749121317     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.07.004     Document Type: Article

References (34)

1. Yamagishi S., Fukami K., Ueda S., and Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 8 (2007) 952-959
2. Taft J.L., Nolan C.J., Yeung S.P., Hewitson T.D., and Martin F.I. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 43 (1994) 1046-1051
3. Ziyadeh F.N., and Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int 39 (1991) 464-475
4. Soldatos G., and Cooper M.E. Diabetic nephropathy: important pathophysiologic mechanisms. Diab Res Clin Pract 82 (2008) S75-S79
5. Cravedi P., Ruggenenti P., and Remuzzi G. Intensified inhibition of renin-angiotensin system: a way to improve renal protection?. Curr Hypertens Rep 9 (2005) 430-436
6. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
7. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11 (2005) 2279-2299
8. Yamagishi S., Nakamura K., Matsui T., Ueda S., Fukami K., and Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 17 (2008) 983-996
9. Yamagishi S., Nakamura K., Matsui T., Noda Y., and Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 14 (2008) 487-495
10. Fukami K., Yamagishi S., Ueda S., and Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 14 (2008) 946-952
11. Miyata T., van Ypersele de Strihou C., Ueda Y., Ichimori K., Inagi R., Onogi H., et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13 (2002) 2478-2487
12. Forbes J.M., Cooper M.E., Thallas V., Burns W.C., Thomas M.C., Brammar G.C., et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51 (2001) 3274-3282
13. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 281 (2006) 20213-20220
14. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M., et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 277 (2002) 20309-20315
15. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., and Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 63 (2003) 464-473
16. Yamagishi S., Inagaki Y., Amano S., Okamoto T., Takeuchi M., and Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 296 (2002) 877-882
17. Unoki H., Bujo H., Yamagishi S., Takeuchi M., Imaizumi T., and Saito Y. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diab Res Clin Pract 76 (2007) 236-244
18. Matsui T., Yamagishi S., Ueda S., Nakamura K., Imaizumi T., Takeuchi M., et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 35 (2007) 482-489
19. Takenaka K., Yamagishi S., Jinnouchi Y., Nakamura K., Matsui T., and Imaizumi T. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci 77 (2005) 3231-3241
20. Yamagishi S., Matsui T., Nakamura K., Inoue H., Takeuchi M., Ueda S., et al. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res 75 (2008) 130-134
21. Yamagishi S., Matsui T., Nakamura K., Inoue H., Takeuchi M., Ueda S., et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res 40 (2008) 10-15
22. Yamagishi S., Matsui T., Nakamura K., Takeuchi M., and Inoue H. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Protein Pept Lett 15 (2008) 850-853
23. Matsui T., Nakamura K., Takeuchi M., and Yamagishi S. Telmisartan blocks advanced glycation end product (AGE)-induced plasminogen activator inhibitor-1 (PAI-1) gene expression in endothelial cells via activation of peroxisome proliferator-activated receptor-γ (PPAR-γ). Lett Drug Des Dis 5 (2008) 477-480
24. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 294 (2008) F697-701
25. Cooper M.E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44 (2001) 1957-1972
26. Lassila M., Fukami K., Jandeleit-Dahm K., Semple T., Carmeliet P., Cooper M.E., et al. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia 50 (2007) 1315-1326
27. Takeuchi M., Makita Z., Yanagisawa K., Kameda K., and Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med 5 (1999) 393-405
28. Miura J., Yamagishi S., Uchigata Y., Takeuchi M., Yamamoto H., Makita Z., et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J Diab Complicat 17 (2003) 16-21
29. Marino M.R., Langenbacher K., Ford N.F., and Uderman H.D. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 138 (1998) 246-255
30. Nakamura K., Yamagishi S., Nakamura Y., Takenaka K., Matsui T., Jinnouchi Y., et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70 (2005) 137-141
31. Yamagishi S., Takeuchi M., Matsui T., Nakamura K., Imaizumi T., and Inoue H. Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 579 (2005) 4265-4270
32. Matsui T., Yamagishi S., Nakamura K., Inoue H., and Takeuchi M. Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells. J Int Med Res 35 (2007) 107-112
33. Matsui T., Yamagishi S., Takeuchi M., Ueda S., Fukami K., and Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 385 (2009) 269-272
34. Bhaskaran M., Reddy K., Radhakrishanan N., Franki N., Ding G., and Singhal P.C. Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol 284 (2003) F955-F965